• Recruiting

NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

Updated: May 24

REST

NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

rest - Isa RVD

Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the study. All participants will receive isatuximab in combination with bortezomib, lenalidomide and minimal dexamethasone until disease progression. The primary objective of this study is the MRD negativity rate during and/or after first 18 cycles of study treatment.


Sponsor

Oslo University Hospital


Collaborators

Nordic Myeloma Study Group

St. Olavs Hospital

Helse Stavanger HF


Information provided by (Responsible Party)

Fredrik Hellem Schjesvold, Oslo University Hospital


Location

Norway

 

ClinicalTrials.gov Identifier: NCT04939844


Official Title: Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma


First Posted: June 25, 2021


Click here for details on ClinicalTrials.gov

 

Drug: Isatuximab, bortezomib, lenalidomide, dexamethasone

 

Location

Europe

Norway






Posts Archive